Sedhain A, et al. - In this prospective, open-label, randomized trial, researchers compared low dose mycophenolate mofetil (MMF) to cyclophosphamide (CYC) with respect to efficacy and safety, when used in induction therapy of lupus nephritis (LN) in Nepalese population. In this study including 49 patients with class III to V lupus nephritis, out of which 42 patients (21 in each group) could complete the study, the following treatment regimens were used: CYC was given intravenously as a monthly pulse and MMF was administered orally in the tablet form in the maximum daily dose of 1.5 g in two divided doses. They found that MMF vs CYC displayed equal efficacy in inducing remission with attenuation of proteinuria and improvement of kidney function with lesser adverse events, when used in relatively lower dose in the induction therapy of proliferative lupus nephritis.